NEW YORK — Cellectricon said on Tuesday that it has signed an agreement to use StressMarq Biosciences' reagents for its neurodegenerative research.
Mölndal, Sweden-based Cellectricon provides drug discovery services, with a focus on chronic pain and neurodegenerative disease. Among its areas of research is the spread of neurodegenerative disease-associated peptides, such as amyloid-beta peptides, tau, and alpha-synuclein, that characterizes Alzheimer's disease and Parkinson's disease.